Intellia Therapeutics, Inc
Here’s whether Intellia Therapeutics, Inc (NTLA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+0.55% over 10 days); RSI 49 — healthy momentum range; strong 1-year return of +78.6%. Concerns: below the 50-day MA (medium-term momentum negative); declining volume on rally — weak conviction (0.63x 30d avg). Currently 52.1% off its 52-week high. Score: +3/7.
NTLA is holding above its long-term 200-day MA ($13.35) but has slipped below the 50-day MA ($13.63), pointing to short-term weakness in an otherwise intact trend. An RSI of 49.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +78.6% compares to +24.4% for SPY (beat the market by 54.3%). The current 52.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.